Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
4.790
-0.210 (-4.20%)
Feb 21, 2025, 4:00 PM EST - Market closed
Silence Therapeutics Revenue
Silence Therapeutics had revenue of 1.14M GBP in the quarter ending September 30, 2024, a decrease of -59.19%. This brings the company's revenue in the last twelve months to 16.25M, down -42.07% year-over-year. In the year 2023, Silence Therapeutics had annual revenue of 25.38M with 44.99% growth.
Revenue (ttm)
16.25M GBP
Revenue Growth
-42.07%
P/S Ratio
9.72
Revenue / Employee
149,037 GBP
Employees
109
Market Cap
226.16M USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 25.38M | 7.87M | 44.99% |
Dec 31, 2022 | 17.50M | 5.09M | 40.97% |
Dec 31, 2021 | 12.42M | 6.94M | 126.59% |
Dec 31, 2020 | 5.48M | 5.24M | 2,145.49% |
Dec 31, 2019 | 244.00K | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SLN News
- 9 days ago - Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 - Business Wire
- 2 months ago - Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
- 2 months ago - Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting - Business Wire
- 3 months ago - Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference - Business Wire
- 3 months ago - Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst - Benzinga
- 3 months ago - Top 3 Health Care Stocks You'll Regret Missing In Q4 - Benzinga
- 3 months ago - Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting - Business Wire
- 3 months ago - Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Business Wire